Related Experiment Video

Updated: May 9, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?

Fadi S Farhat1, Wissam Houhou

  • 1Hematology-Oncology Division (Head), Hammoud Hospital University Medical Center, Ghassan Hammoud Street, 652, Saida, Lebanon.

Therapeutic Advances in Medical Oncology
|July 17, 2013
PubMed

Insights

New targeted therapies are improving outcomes for non-small cell lung cancer (NSCLC) patients. This review covers approved and emerging drugs, including those targeting vascular endothelial growth factor and epidermal growth factor receptor.

Area of Science:

  • Oncology
  • Pharmacology
  • Therapeutics

Background:

  • Non-small cell lung cancer (NSCLC) treatment is rapidly advancing.
  • There is a growing number of targeted drugs offering improved patient outcomes and safety.
  • Current therapeutic strategies include monotherapy and combination therapies for various treatment lines.

Purpose of the Study:

  • To review approved and investigational targeted drugs for non-small cell lung cancer (NSCLC).
  • To summarize experience with drugs targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR).
  • To provide an overview of novel therapeutic targets and early-phase agents in NSCLC.

Main Methods:

  • Literature review of approved and emerging targeted therapies for NSCLC.
  • Summary of clinical experience with VEGF and EGFR inhibitors.
  • Exploration of novel targets and early-stage therapeutic agents.

Main Results:

  • Several targeted drugs are approved or under evaluation for NSCLC treatment.
  • Established therapies targeting VEGF and EGFR have demonstrated efficacy.
  • Emerging novel targets and their corresponding agents show promise in early investigations.

Conclusions:

  • The landscape of NSCLC therapeutics is continuously evolving with new targeted agents.
  • Targeted therapies, including those against VEGF and EGFR, are crucial in managing NSCLC.
  • Further research into novel targets and agents is essential for advancing NSCLC treatment.
Keywords:
monoclonal antibodynon-small cell lung cancertherapytyrosine kinase inhibitor

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.